All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

How might CAR T-cells change the treatment landscape for patients with CLL?

Mar 9, 2022

During the 4th European CAR T-Cell Meeting, the Lymphoma Hub was pleased to speak with Julio Delgado, Hospital Clínic de Barcelona, Barcelona, ES. We asked, How might CAR T-cells change the treatment landscape for patients with chronic lymphocytic leukemia (CLL)?

How might CAR T-cells change the treatment landscape for patients with CLL?

Delgado begins by outlining the recent improvements in CLL treatment, including new drug approvals (such as BTK and BCL-2 inhibitors). On the other hand, there are also patients (e.g., those with high-risk cytogenetics or for whom other therapies have failed) who are being referred for CAR-T therapy. However, Delgado highlights that there are no CAR-T cell products approved in the EU, meaning patients need to be enrolled in trials. Finally, Delgado gives his recommendations on treatment choices for high-risk CLL.


Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Your opinion matters

What kind of 1L DLBCL patients should now be treated with Pola-R-CHP (choose all options that apply)?
4 votes - 1 day left ...


Subscribe to get the best content related to lymphoma & CLL delivered to your inbox